Irras Expands its Management Group

STOCKHOLM, Oct. 19, 2018 /PRNewswire/ --

IRRAS AB (Nasdaq First North Premier: IRRAS) announced today that, as of October 19, the IRRAS management consists of the following groups and persons:

                 Executive Management Team


      Kleanthis G. Xanthopoulos, Ph.D.     
     President & CEO



     Fredrik Alpsten                      
     CFO and Deputy CEO



     Will Martin                            Chief Commercial Officier



     Lance Boling                           Vice President, Product
                                              Development



     Kellie Fontes                          Senior Director, Human Capital




                 Extended Management Group



     Adam Sampson                           Vice President, Product
                                              Excellence



     Dino De Cicco                          Senior Director, Product
                                              Development



     Dessi Lyakov                           Director, Regulatory & Quality



     Sabina Berlin                        
     Vice President, Finance

Simultaneously with the above mentioned management changes, Karl-Matthias Moehlmann, Senior Vice President, Commercial Operations and General Manager, Europe, has left IRRAS.

For more information, please contact:

     
                US             
     
                Europe


      Kleanthis G. Xanthopoulos,
       Ph.D.                      
     Fredrik Alpsten



     President & CEO             
     CFO and Deputy CEO


                                  
     +46-706-67-31-06


                   info@irras.com 
     
                fredrik.alpsten@irras.com

About IRRAS

IRRAS AB (Nasdaq First North Premier: IRRAS) is a publicly-traded, commercial-stage medical technology company focused on developing and commercializing innovative solutions for brain surgery. The company's initial product, IRRAflow®, addresses the complications associated with the current methods of managing intracranial fluid by using a dual lumen catheter that combines active irrigation with ongoing fluid drainage. IRRAflow received FDA clearance in July 2018.

Regularly during treatment, the IRRAflow catheter is automatically flushed to prevent common catheter occlusions from forming. Because IRRAflow is a completely closed system, it is designed to reduce the documented infection risk of these procedures. Additionally, IRRAflow incorporates ICP monitoring and uses a proprietary software to regulate treatment based on desired pressure levels.

With its unique product portfolio, protected by property patents and patent applications, IRRAS is well positioned to establish a leadership position in the medical device market. IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com

IRRAS AB (publ) is listed on Nasdaq First North Premier. Wildeco is certified adviser of the company.

This document is considered information that IRRAS is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person above, on October 19, 2018 at 8.00 a.m. (CET).

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/irras/r/irras-expands-its-management-group,c2648583

The following files are available for download:

     
     http://mb.cision.com/Main/16550/2648583/929028.pdf Press release (PDF)

View original content:http://www.prnewswire.com/news-releases/irras-expands-its-management-group-300734218.html

SOURCE IRRAS